Intellia Therapeutics (NTLA) Q1 2026 earnings summary

Executive summary

• Achieved positive topline Phase 3 results for lonvo-z in hereditary angioedema (HAE), meeting all primary and key secondary endpoints with strong efficacy and safety results; commercial launch planned for 1H 2027.

• Advanced two lead CRISPR-based therapies, lonvo-z for HAE and nex-z for transthyretin (ATTR) amyloidosis, both in Phase 3 clinical development.

• Initiated rolling BLA submission for lonvo-z, targeting completion in 2H 2026 and U.S. launch in 1H 2027.

• FDA lifted clinical holds on both MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z, allowing resumption of enrollment and patient screening.

• Collaboration with Regeneron continues to provide revenue and cost-sharing for the ATTR program.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $517.2 million at quarter-end, down from $605.1 million at year-end 2025.

• Collaboration revenue was $15.0 million for Q1 2026, down $1.6 million year-over-year due to lower AvenCell revenue and prior year Regeneron milestone.

• Research and development expenses decreased 26% to $80.7 million, reflecting lower external spend, workforce reduction, and lower stock-based compensation.

• General and administrative expenses increased 20% to $34.8 million, driven by legal and commercial buildout costs.

• Net loss narrowed to $96.2 million from $114.3 million year-over-year.

Outlook and guidance

• Cash and securities, including April 2026 equity offering proceeds, expected to fund operations into 2028, well beyond anticipated lonvo-z U.S. launch.

• Research and development expenses expected to decrease in 2026 as focus shifts to high-value programs and commercial launch preparation.

• BLA submission for lonvo-z expected to complete in 2H 2026; U.S. launch planned for 1H 2027.

• MAGNITUDE-2 enrollment for nex-z targeted for completion in 2H 2026.